mitomycin has been researched along with Biliary Tract Cancer in 21 studies
Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this study was to determine the efficacy and safety of infusional 5-fluorouracil (5-FU), doxorubicin, and mitomycin-C (iFAM) as salvage chemotherapy in biliary tract cancer (BTC) and to identify prognostic factors." | 9.16 | Outcome of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) chemotherapy and analysis of prognostic factors in patients with refractory advanced biliary tract cancer. ( Bang, YJ; Han, SW; Im, SA; Kim, TY; Lim, KH; Oh, DY, 2012) |
| "Gemcitabine-based chemotherapy is a commonly used first-line treatment for patients with pancreatic and biliary tract cancer." | 9.14 | Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer. ( Jeong, JS; Kim, BG; Kim, HJ; Kim, SH; Kim, YH; Kwon, HC; Lee, S; Oh, SY; Rho, MH; Rho, MS, 2009) |
| "Based on a recent pharmacokinetic study suggesting that high biliary levels of mitomycin C (MMC) may be achieved as a result of an entero-hepatic recycling mechanism, we conducted a Phase II EORTC trial which involved MMC administration to patients with non-resectable biliary tract carcinoma." | 9.07 | Phase II trial of mitomycin C (MMC) in advanced gallbladder and biliary tree carcinoma. An EORTC Gastrointestinal Tract Cancer Cooperative Group Study. ( Audisio, RA; Bleiberg, H; Blijham, GH; Duez, N; Neijt, JP; Sahmoud, T; Taal, BG; Veenhof, CH, 1993) |
| " The aim was to investigate the therapeutic efficacy and tolerance of mitomycin C (MMC) in combination with gemcitabine (GEM) or capecitabine (CAPE) in previously untreated patients with advanced biliary tract cancer." | 6.71 | Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial. ( Depisch, D; Gruenberger, T; Karall, K; Kornek, GV; Laengle, F; Lang, F; Penz, M; Scheithauer, W; Schuell, B, 2004) |
| "The purpose of this study was to determine the efficacy and safety of infusional 5-fluorouracil (5-FU), doxorubicin, and mitomycin-C (iFAM) as salvage chemotherapy in biliary tract cancer (BTC) and to identify prognostic factors." | 5.16 | Outcome of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) chemotherapy and analysis of prognostic factors in patients with refractory advanced biliary tract cancer. ( Bang, YJ; Han, SW; Im, SA; Kim, TY; Lim, KH; Oh, DY, 2012) |
| "Gemcitabine-based chemotherapy is a commonly used first-line treatment for patients with pancreatic and biliary tract cancer." | 5.14 | Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer. ( Jeong, JS; Kim, BG; Kim, HJ; Kim, SH; Kim, YH; Kwon, HC; Lee, S; Oh, SY; Rho, MH; Rho, MS, 2009) |
| "We have reported a 33% partial response rate with acceptable toxicity using weekly 24-h infusion of high-dose 5-fluorouracil (5-FU) and leucovorin (LV) in patients with far advanced biliary tract cancers (BTC)." | 5.09 | Mitomycin C with weekly 24-h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract and periampullar carcinomas. ( Chen, JS; Jan, YY; Liau, CT; Lin, YC, 2001) |
| "Based on a recent pharmacokinetic study suggesting that high biliary levels of mitomycin C (MMC) may be achieved as a result of an entero-hepatic recycling mechanism, we conducted a Phase II EORTC trial which involved MMC administration to patients with non-resectable biliary tract carcinoma." | 5.07 | Phase II trial of mitomycin C (MMC) in advanced gallbladder and biliary tree carcinoma. An EORTC Gastrointestinal Tract Cancer Cooperative Group Study. ( Audisio, RA; Bleiberg, H; Blijham, GH; Duez, N; Neijt, JP; Sahmoud, T; Taal, BG; Veenhof, CH, 1993) |
| "To develop a specific chemotherapy modality for the perineural invasion of neural cell adhesion molecule (NCAM) positive biliary tract cancer, an anticancer drug, mitomycin C (MMC), was covalently bound to anti-NCAM monoclonal antibody (anti-NCAM MoAb) to form a conjugate using the cyanogen bromide method." | 3.70 | Preparation of a conjugate of mitomycin C and anti-neural cell adhesion molecule monoclonal antibody for specific chemotherapy against biliary tract carcinoma. ( Koyama, K; Kusano, T; Saito, Y; Sato, E; Tanaka, J, 1998) |
| "A phase II trial of the regimen 5-fluorouracil, doxorubicin, and mitomycin C (FAM) was conducted in 17 patients with advanced or recurrent biliary tract cancer." | 3.67 | 5-Fluorouracil, mitomycin, and doxorubicin (FAM) in carcinoma of the biliary tract. ( Harvey, JH; Schein, PS; Smith, FP, 1984) |
| " The aim was to investigate the therapeutic efficacy and tolerance of mitomycin C (MMC) in combination with gemcitabine (GEM) or capecitabine (CAPE) in previously untreated patients with advanced biliary tract cancer." | 2.71 | Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial. ( Depisch, D; Gruenberger, T; Karall, K; Kornek, GV; Laengle, F; Lang, F; Penz, M; Scheithauer, W; Schuell, B, 2004) |
| "They include intrahepatic and extrahepatic cholangiocarcinomas, gallbladder carcinomas, and ampullary carcinomas." | 2.58 | Gemcitabine-based chemotherapy for advanced biliary tract carcinomas. ( Abdel-Rahman, O; Elhalawani, H; Elsayed, Z, 2018) |
| "One case of each of ovarian cancer and gastric cancer showed minor response." | 1.27 | [A clinical trial of a new mitomycin C derivative, KW-2083 (7-N-(p-hydroxyphenyl)-mitomycin C)]. ( Takahashi, H; Takahashi, K; Wakui, A; Yokoyama, M, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (14.29) | 18.7374 |
| 1990's | 11 (52.38) | 18.2507 |
| 2000's | 4 (19.05) | 29.6817 |
| 2010's | 3 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abdel-Rahman, O | 1 |
| Elsayed, Z | 1 |
| Elhalawani, H | 1 |
| Cereda, S | 1 |
| Milella, M | 1 |
| Cordio, S | 1 |
| Leone, F | 1 |
| Aprile, G | 1 |
| Galiano, A | 1 |
| Mosconi, S | 1 |
| Vasile, E | 1 |
| Santini, D | 1 |
| Belli, C | 1 |
| Auriemma, A | 1 |
| Novarino, A | 1 |
| Vaccaro, V | 1 |
| Martines, C | 1 |
| Marino, D | 1 |
| Lutrino, SE | 1 |
| Palazzo, V | 1 |
| Reinach, B | 1 |
| Aldrighetti, L | 1 |
| Reni, M | 1 |
| Lee, S | 1 |
| Oh, SY | 1 |
| Kim, BG | 1 |
| Kwon, HC | 1 |
| Kim, SH | 1 |
| Rho, MH | 1 |
| Kim, YH | 1 |
| Rho, MS | 1 |
| Jeong, JS | 1 |
| Kim, HJ | 1 |
| Lim, KH | 1 |
| Han, SW | 1 |
| Oh, DY | 1 |
| Im, SA | 1 |
| Kim, TY | 1 |
| Bang, YJ | 1 |
| Kornek, GV | 2 |
| Schuell, B | 1 |
| Laengle, F | 1 |
| Gruenberger, T | 1 |
| Penz, M | 1 |
| Karall, K | 1 |
| Depisch, D | 1 |
| Lang, F | 2 |
| Scheithauer, W | 2 |
| Yonemoto, N | 1 |
| Furuse, J | 1 |
| Okusaka, T | 1 |
| Yamao, K | 1 |
| Funakoshi, A | 1 |
| Ohkawa, S | 1 |
| Boku, N | 1 |
| Tanaka, K | 1 |
| Nagase, M | 1 |
| Saisho, H | 1 |
| Sato, T | 1 |
| Harvey, JH | 1 |
| Smith, FP | 1 |
| Schein, PS | 1 |
| Sato, M | 1 |
| Ishidoya, T | 1 |
| Joko, Y | 1 |
| Kiyasu, Y | 1 |
| Sakai, K | 1 |
| Kimura, S | 1 |
| Taal, BG | 1 |
| Audisio, RA | 1 |
| Bleiberg, H | 1 |
| Blijham, GH | 1 |
| Neijt, JP | 1 |
| Veenhof, CH | 1 |
| Duez, N | 1 |
| Sahmoud, T | 1 |
| Takada, T | 2 |
| Kato, H | 2 |
| Matsushiro, T | 2 |
| Nimura, Y | 1 |
| Nagakawa, T | 1 |
| Nakayama, T | 1 |
| Yamauchi, H | 2 |
| Ogata, Y | 1 |
| Shimada, H | 1 |
| Miyakawa, S | 1 |
| Yamaguchi, A | 1 |
| Sakoda, K | 1 |
| Yasuda, H | 1 |
| Tsukada, K | 1 |
| Yoshida, K | 2 |
| Ashida, H | 1 |
| Ishikawa, Y | 1 |
| Kotoura, Y | 1 |
| Kinoshita, H | 1 |
| Kajiwara, T | 1 |
| Watanabe, G | 2 |
| Uchimura, M | 1 |
| Funabiki, T | 1 |
| Ikeda, S | 1 |
| Okada, S | 2 |
| Polyzos, A | 1 |
| Nikou, G | 1 |
| Giannopoulos, A | 1 |
| Toskas, A | 1 |
| Kalahanis, N | 1 |
| Papargyriou, J | 1 |
| Michail, P | 1 |
| Papachristodoulou, A | 1 |
| Tanaka, J | 1 |
| Sato, E | 1 |
| Saito, Y | 1 |
| Kusano, T | 1 |
| Koyama, K | 1 |
| Raderer, M | 1 |
| Hejna, MH | 1 |
| Valencak, JB | 1 |
| Weinländer, GS | 1 |
| Bareck, E | 1 |
| Lenauer, J | 1 |
| Brodowicz, T | 1 |
| Higashi, S | 1 |
| Kato, C | 1 |
| Sakumoto, H | 1 |
| Sumiyoshi, K | 1 |
| Takahahsi, T | 1 |
| Matsumoto, K | 1 |
| Kane, T | 1 |
| Sakoda, M | 1 |
| Takahashi, M | 1 |
| Hosono, Y | 1 |
| Asano, M | 1 |
| Yamamoto, A | 1 |
| Chen, JS | 1 |
| Lin, YC | 1 |
| Jan, YY | 1 |
| Liau, CT | 1 |
| Sasaki, M | 1 |
| Kajihara, T | 1 |
| Hanaue, H | 1 |
| Shimizu, T | 1 |
| Yamazaki, S | 1 |
| Goseki, N | 1 |
| Endo, M | 1 |
| Minsky, BD | 1 |
| Kemeny, N | 1 |
| Armstrong, JG | 1 |
| Reichman, B | 1 |
| Botet, J | 1 |
| Abad, A | 1 |
| Rosell, R | 1 |
| Barnadas, A | 1 |
| Carles, J | 1 |
| Ribelles, N | 1 |
| Solano, V | 1 |
| Okazaki, N | 1 |
| Takahashi, K | 1 |
| Yokoyama, M | 1 |
| Takahashi, H | 1 |
| Wakui, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| PD-1 Antibody Plus Gemcitabine and Oxaliplatin (GEMOX) as Postoperative Adjuvant Therapy in Perihilar Cholangiocarcinoma Patients With Positively Metastatic Lymph Nodes : a Single Arm, Phase II Trial[NCT05430698] | Phase 2 | 62 participants (Anticipated) | Interventional | 2023-01-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for mitomycin and Biliary Tract Cancer
| Article | Year |
|---|---|
Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
Topics: Ampulla of Vater; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; B | 2018 |
11 trials available for mitomycin and Biliary Tract Cancer
| Article | Year |
|---|---|
Capecitabine with/without mitomycin C: results of a randomized phase II trial of second-line therapy in advanced biliary tract adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms | 2016 |
Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms | 2009 |
Outcome of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) chemotherapy and analysis of prognostic factors in patients with refractory advanced biliary tract cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Diseas | 2012 |
Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Bo | 2004 |
Phase II trial of mitomycin C (MMC) in advanced gallbladder and biliary tree carcinoma. An EORTC Gastrointestinal Tract Cancer Cooperative Group Study.
Topics: Biliary Tract Neoplasms; Carcinoma; Female; Gallbladder Neoplasms; Humans; Male; Middle Aged; Mitomy | 1993 |
[Prospective randomized trial comparing 1/2 FAM (5-fluorouracil (5-FU) + adriamycin + mitomycin C) versus palliative therapy for the treatment of unresectable pancreatic and biliary tract carcinomas (the 2nd trial in non-resectable patients). Japanese Stu
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Doxorubicin; F | 1996 |
Chemotherapy of biliary tract cancer with mitomycin-C and 5-fluorouracil biologically modulated by folinic acid. A phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Drug Administration S | 1996 |
Two consecutive phase II studies of 5-fluorouracil/leucovorin/mitomycin C and of gemcitabine in patients with advanced biliary cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined C | 1999 |
[Arterial infusion therapy with implantable port for inoperable hepatobiliary tumors].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neopla | 1999 |
Mitomycin C with weekly 24-h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract and periampullar carcinomas.
Topics: Adenocarcinoma; Adult; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Bilia | 2001 |
[Prospective randomized trial comparing modified FAM (5-fluorouracil (5-FU) + adriamycin + mitomycin C) versus 5-FU alone for the treatment of non-resectable pancreatic and biliary tract carcinomas (the 1st trial in non-resectable patients). Study Group o
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Chemotherapy, | 1992 |
9 other studies available for mitomycin and Biliary Tract Cancer
| Article | Year |
|---|---|
A multi-center retrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisp | 2007 |
5-Fluorouracil, mitomycin, and doxorubicin (FAM) in carcinoma of the biliary tract.
Topics: Adenoma, Bile Duct; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neopl | 1984 |
[Constant intra-aortic infusion chemotherapy for advanced abdominal cancer--a technic and the effect in patients with peritoneal metastases].
Topics: Abdominal Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Coloni | 1984 |
Preparation of a conjugate of mitomycin C and anti-neural cell adhesion molecule monoclonal antibody for specific chemotherapy against biliary tract carcinoma.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Biliary Tract Neoplasms; Cell Adhesion Molecule | 1998 |
[Nutritional therapy of patient with advanced biliary tract cancer].
Topics: Biliary Tract Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans; Middle Aged; Mitom | 1991 |
Extrahepatic biliary system cancer: an update of a combined modality approach.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Brach | 1991 |
5-fluorouracil, ifosfamide and mitomycin (FIM) combination for pancreatic-biliary tumors.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bili | 1991 |
[Chemotherapy in cancers of the gallbladder and bile ducts].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cytarabine; | 1991 |
[A clinical trial of a new mitomycin C derivative, KW-2083 (7-N-(p-hydroxyphenyl)-mitomycin C)].
Topics: Adult; Aged; Animals; Antibiotics, Antineoplastic; Biliary Tract Neoplasms; Colonic Neoplasms; Colon | 1985 |